On Monday, H.C. Wainwright reaffirmed its Buy rating and $17.00 price target for Cogent Biosciences, a company trading on NASDAQ under the ticker NASDAQ:COGT. The firm's decision follows Cogent's recent presentation of preclinical results for its drug candidate CGT6297 at the EORTC-NCI-AACR symposium.
CGT6297, which is an allosteric inhibitor of PI3K, has shown 25-fold selectivity over the PI3Kα WT variant. This preclinical data suggests that CGT6297 has high oral bioavailability and low clearance across species, which could potentially lead to robust inhibition of downstream signaling and efficacy in animal models.
The analyst from H.C. Wainwright noted that although CGT6297 demonstrated superior efficacy without an increase in insulin levels compared to a clinically relevant dose of an approved therapy in a mouse tumor model, competitors such as OnKure's OKI-219 and Scorpion's STX-478 exhibited greater in vivo anti-tumor efficacy.
Despite the competitive landscape, with OnKure's OKI-219 showing 106x pAKT selectivity and 159x proliferation selectivity in certain cell lines, Cogent's CGT6297 is moving forward with plans to initiate IND-enabling studies in 2025. The firm's confidence in Cogent remains steady, as reflected in the reiterated 12-month price target of $17 per share.
In other recent news, Cogent Biosciences has made significant strides in its clinical trials and development pipeline. The biotechnology firm has introduced a new KRAS inhibitor, CGT6737, and a PI3Kα inhibitor, CGT6297, into its developmental pipeline. These inhibitors are designed to offer significant tumor growth inhibition in preclinical models and offer a better safety profile than existing treatments, respectively. Cogent plans to begin IND-enabling studies for CGT6297 in 2025.
Additionally, the company has successfully completed patient enrollment for its Phase 3 PEAK trial evaluating bezuclastinib for the treatment of gastrointestinal stromal tumors (GIST). Top-line results from this trial are expected by the end of 2025. Furthermore, Cogent's SUMMIT trial for nonadvanced systemic mastocytosis is on track to complete enrollment in the first quarter of 2025, with results expected in the second half of the same year.
Various financial firms have adjusted their stock price targets and ratings for Cogent following these recent developments. Citi raised its price target from $13.00 to $15.00, maintaining a Buy rating, while Baird increased its price target to $10.00, keeping a Neutral rating. H.C. Wainwright reduced its 12-month price target to $17, but reaffirmed a Buy rating. Piper Sandler reaffirmed its Overweight rating with a $22.00 price target.
InvestingPro Insights
Cogent Biosciences' recent preclinical data presentation and H.C. Wainwright's reaffirmed Buy rating align with some interesting financial metrics and insights from InvestingPro. The company's market cap stands at $1.28 billion, reflecting investor interest in its potential.
InvestingPro Tips highlight that Cogent holds more cash than debt on its balance sheet, which could be crucial for funding its ongoing research and development efforts, including the advancement of CGT6297 towards IND-enabling studies. This strong cash position is further supported by the fact that liquid assets exceed short-term obligations, providing financial flexibility as the company progresses its pipeline.
However, it's important to note that Cogent is not currently profitable, with a negative P/E ratio of -5.65 over the last twelve months as of Q2 2024. This is not uncommon for biopharmaceutical companies in the development stage, and aligns with the InvestingPro Tip indicating that analysts do not anticipate the company will be profitable this year.
Despite these challenges, Cogent's stock has shown strong performance, with a 55.64% price total return over the past six months and is trading near its 52-week high. This suggests that investors are optimistic about the company's potential, possibly influenced by developments like the CGT6297 preclinical results.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide further insights into Cogent Biosciences' financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.